-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $60

Benzinga·04/29/2026 17:49:12
Listen to the news
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $50 to $60.